GLP1R and heart failure: In a US claims-based study with follow-up to two years (n = 47,343), Htoo et al. 106 reported a higher relative risk of MACE with SGLT2i compared to GLP1-RA specific to individuals without CVD and heart failure (Relative risk [RR] 1.31 [95% CI 1.09, 1.56]), and a higher risk of stroke with SGLT2i versus GLP1-RA specific to individuals without CVD (No CVD without heart failure: RR 1.62 [95%CI 1.10, 2.38]; No CVD with heart failure: RR 3.30 [95%CI 1.22, 8.97]).